Nanomedical Diagnostics ^Company

Nanomedical Diagnostics has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that provides real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules ≥1 Da in complex media such as DMSO, using unprecedentedly small amounts of sample, making the platform a novel orthogonal technique for drug discovery hit validation and lead optimization.
As the world’s only provider of graphene biosensors, our mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms.